Page 118 - Read Online

Hann et al. Urine markers for HCC monitoring

can overcome the inherent limitations of imaging Gastroenterol 2014;20:4160-6.
technology, and to provide a highly sensitive tool for 9. Minami Y, Kudo M. Imaging Modalities for assessment of treatment
monitoring HCC recurrence. response to nonsurgical hepatocellular carcinoma therapy: contrast-
enhanced US, CT, and MRI. Liver Cancer 2015;4:106-14.
Authors’ contributions 10. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y,
Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi
Concept/design: H.W. Hann, S. Jain, W. Song, Y.H. Su K, Shiratori Y. Lamivudine treatment in patients with HBV-related
Clinical sample preparation: H.W. Hann, G. Park hepatocellular carcinoma -- using an untreated, matched control
Experimental analysis: S. Jain, Y.H. Su cohort. Acta Med Okayama 2005;59:217-24.
Manuscript preparation: H.W. Hann, S. Jain, W. Song, 11. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk
J. Steffen, Y.H. Su factors and prognosis for early and late intrahepatic recurrence after
Manuscript review: H.W. Hann, S. Jain, W. Song, J. resection of hepatocellular carcinoma. Cancer 2000;89:500-7.
Steffen, Y.H. Su 12. Hann HW, Coben R, Brown D, Needleman L, Rosato E, Min A, Hann
RS, Park KB, Dunn S, DiMarino AJ. A long-term study of the effects
of antiviral therapy on survival of patients with HBV-associated
Financial support and sponsorship hepatocellular carcinoma (HCC) following local tumor ablation.
This work has been supported by the National Institute Cancer Med 2014;3:390-6.
of Health R44 CA165312, RO1 CA202769, and R43 13. Kim BK, Park JY, Kim DY, Kim JK, Kim KS, Choi JS, Moon BS,
CA192507. Han KH, Chon CY, Moon YM, Ahn SH. Persistent hepatitis B viral
replication affects recurrence of hepatocellular carcinoma after
Conflicts of interest curative resection. Liver Int 2008;28:393-401.
W. Song is an employee and shareholder of JBS 14. Hann HW, Bergin D, Coben R, DiMarino AJ. Prevention of new
hepatocellular carcinoma with concomitant antiviral therapy in
Science, Inc.; S. Jain and J. Steffen are employees of chronic hepatitis B patients whose initial tumor was successfully
JBS Science, Inc; all other authors declare they have ablated. Int J Cancer 2011;128:739-42.
no other competing interests that exist. 15. Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST.
Impact of antiviral therapy on the survival of patients after major
Patient consent hepatectomy for hepatitis B virus-related hepatocellular carcinoma.
In this prospective study, each patient was informed of Arch Surg 2011;146:675-81.
this study and gave their consent. 16. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT.
Association between nucleoside analogues and risk of hepatitis B
Ethics approval virus-related hepatocellular carcinoma recurrence following liver
resection. JAMA 2012;308:1906-14.
This study was conducted under the approval of 17. Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka
the Institutional Review Board at Thomas Jefferson Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H. Efficacy of
University Hospital, Philadelphia, PA. antiviral therapy with lamivudine after initial treatment for hepatitis
B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol
REFERENCES 2007;22:1929-35.
18. Hann HW, Li D, Yamada H, Satomura S, Coben R, DiMarino AJ.
1. Hung IF, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, Fung Usefulness of highly sensitive AFP-L3 and DCP in surveillance for
JY, Chan AC, Yuen JC, Tiu R, Choi O, Lai CL, Yuen MF. Risk hepatocellular carcinoma in patients with a normal Alpha-Fetoprotein.
factors and post-resection independent predictive score for the J Med Microbiol Diagn 2014;3:1-6.
recurrence of hepatitis B-related hepatocellular carcinoma. PLoS One 19. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens
2016;11:e0148493. culinaris agglutinin-reactive α-fetoprotein and Des-γ-Carboxy
2. Chong CC, Lee KF, Ip PC, Wong JS, Cheung SY, Wong J, Ho SC, prothrombin in histologically proven hepatocellular carcinoma in the
Lai PB. Pre-operative predictors of post-hepatectomy recurrence United States. Dig Dis Sci 2007;52:776-82.
of hepatocellular carcinoma: can we predict earlier? Surgeon 20. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging
2012;10:260-6. of hepatocellular carcinoma in the cirrhotic liver: challenges and
3. Marrero JA, Pelletier S. Hepatocellular carcinoma. Clin Liver Dis controversies. Radiology 2008;247:311-30.
2006;10:339-51. 21. Yu JS. Hepatocellular carcinoma after transcatheter arterial
4. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med chemoembolization: difficulties on imaging follow-up. Korean J
2008;359:2045-7. Radiol 2005;6:134-5.
5. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001;34:1225-41. 22. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma.
6. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio Mol Clin Oncol 2013;1:593-8.
GA, Giulini SM. Early and late recurrence after liver resection for 23. Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid biopsy of
hepatocellular carcinoma: prognostic and therapeutic implications. hepatocellular carcinoma: circulating tumor-derived biomarkers. Dis
Ann Surg 2006;243:229-35. Markers 2016;2016:1427849.
7. Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki 24. Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD,
T, Shimamura T, Furukawa H, Matsushita M, Todo S. Recurrence Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of
patterns after hepatectomy of hepatocellular carcinoma: implication age: towards implementation of circulating tumour DNA. Nat Rev
of Milan criteria utilization. Ann Surg Oncol 2009;16:1560-71. Cancer 2017;17:223-38.
8. Minami Y, Nishida N, Kudo M. Therapeutic response assessment 25. Su YH, Wang M, Aiamkitsumrit B, Brenner DE, Block TM. Detection
of RFA for HCC: contrast-enhanced US, CT and MRI. World J of K-ras mutation in urine of patients with colorectal cancer. Cancer
110 Hepatoma Research ¦ Volume 3 ¦ June 6, 2017